The need for US biotech Gilead Sciences (Nasdaq: GILD) to replace revenue being lost as its flagship hepatitis drugs face increasing competition was made even clearer with the company’s presentation of its latest quarterly and annual financial results.
Gilead’s revenue for 2017’s fourth quarter, of $5.95 billion, beat forecasts of $5.7 billion but was 18.7% lower than in the same period of 2016.
The company’s fourth-quarter earnings, excluding one-off items, were $1.78 compared to the $2.70 of a year ago. The figure did marginally exceed Wall Street estimates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze